---
title: "VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291383546.md"
description: "William Blair analyst Myles Minter maintained a Hold rating on VistaGen Therapeutics (VTGN). The company's shares closed at $0.23. This aligns with the general street consensus of a Hold rating for the stock."
datetime: "2026-07-01T07:55:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291383546.md)
  - [en](https://longbridge.com/en/news/291383546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291383546.md)
---

# VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst

William Blair analyst Myles Minter maintained a Hold rating on VistaGen Therapeutics yesterday. The company’s shares closed yesterday at $0.23.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Minter covers the Healthcare sector, focusing on stocks such as Moderna, BridgeBio Pharma, and Ionis Pharmaceuticals. According to TipRanks, Minter has an average return of 38.1% and a 64.51% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for VistaGen Therapeutics.

### Related Stocks

- [VTGN.US](https://longbridge.com/en/quote/VTGN.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [VistaGen announces annual shareholder meeting](https://longbridge.com/en/news/294551073.md)
- [VistaGen files Form 3 as director Douglas J. Williamson reports no beneficial ownership](https://longbridge.com/en/news/294516342.md)
- [VistaGen names Douglas J. Williamson to board of directors](https://longbridge.com/en/news/294513769.md)
- [Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth](https://longbridge.com/en/news/290007525.md)
- [Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss](https://longbridge.com/en/news/291318976.md)